> Research Disclaimer: Ipamorelin is a research peptide not approved by the FDA for human therapeutic use (PMID: 42578445). This article summarizes publicly available scientific literature for educational and research purposes only. Not for human use.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2Nal-D-Phe-Lys-NH₂. It belongs to the class of growth hormone secretagogues (GHS) — compounds that stimulate growth hormone release from the pituitary gland by acting as ghrelin mimetics, binding to the ghrelin receptor (GHS-R1a) rather than the GHRH receptor.
What makes Ipamorelin particularly noteworthy in the research literature is its selectivity profile. While earlier GH secretagogues like GHRP-2 and GHRP-6 also stimulate GH release via GHS-R1a, they produce significant off-target effects — particularly ACTH/cortisol elevation and prolactin release. Ipamorelin was specifically designed to retain potent GH-releasing activity while eliminating these unwanted endocrine side effects, making it the most selective GHS-R1a agonist among the commonly studied GHRPs.
The name reflects its peptidomimetic structure: it is an "ipamorphin" analog, derived from structure-activity relationship studies aimed at identifying the minimal pharmacophore for GHS-R1a activation. Ipamorelin was first described by researchers at Novo Nordisk in a landmark 1998 publication that characterized its pharmacological selectivity.
---
Why "Selective"? Ipamorelin vs. GHRP-2 and GHRP-6
The defining characteristic of Ipamorelin in research literature is its exceptional selectivity for GH release over other pituitary hormones. This comparison is central to understanding its research interest:
Hormonal Response Comparison (GHS-R1a Agonists)
| Parameter | GHRP-2 | GHRP-6 | Ipamorelin |
|---|---|---|---|
| GH release | Strong | Strong | Strong |
| Cortisol/ACTH elevation | Significant | Moderate | Minimal |
| Prolactin elevation | Significant | Minimal | Minimal |
| Appetite stimulation | Moderate | Strong (ghrelin-like) | Minimal |
| Ghrelin-like GI effects | Moderate | Strong | Minimal |
| Selectivity for GH | Lower | Lower | Highest |
This selectivity profile emerges from Ipamorelin's structural features. The D-2-naphthylalanine (D-2Nal) and D-phenylalanine (D-Phe) residues at positions 3 and 4, combined with the alpha-aminoisobutyric acid (Aib) at position 1 and the amidated C-terminus, create a conformation that activates GHS-R1a with high efficiency for GH release but without the broad receptor activation that produces cortisol and prolactin responses with earlier GHRPs.
The Original Selectivity Study (PMID 9849822)
The seminal Ipamorelin characterization was published by Raun et al. in 1998 in the European Journal of Endocrinology. This study compared Ipamorelin's endocrine effects to GHRP-2 and GHRP-6 in rat models, establishing:
- •Ipamorelin produced GH release comparable in magnitude to GHRP-6 at equivalent doses
- •Unlike GHRP-2 (which produced >3-fold ACTH and cortisol elevation), Ipamorelin produced no significant ACTH or cortisol response
- •Ipamorelin produced no significant prolactin release at GH-stimulating doses
- •The selectivity was attributed to differential interaction with GHS-R1a subtype versus accessory binding sites responsible for cortisol/prolactin pathways
This paper remains the foundational reference for Ipamorelin's selectivity and is cited in virtually every research discussion of the compound.
---
Mechanism: GHS-R1a Agonism and Selective GH Pulse
Ipamorelin's mechanism of action centers on GHS-R1a activation — the same receptor activated by endogenous ghrelin:
GHS-R1a Signaling Cascade
1. Ipamorelin binds GHS-R1a on pituitary somatotroph cells
2. Gαq/phospholipase C/IP₃ signaling is activated
3. Intracellular calcium mobilization triggers GH secretory granule exocytosis
4. Pulsatile GH release into circulation
GHS-R1a Biology and GH Release
Research on GHS-R1a pharmacology established the receptor's expression pattern, binding kinetics, and downstream signaling for selective GH release. This work characterized how compounds with different structural features can preferentially activate GH release pathways without triggering the ACTH/prolactin responses associated with less selective GHS-R1a engagement.
No Feedback Mechanism Disruption
An important research consideration: Ipamorelin stimulates GH release without directly suppressing somatostatin (the endogenous GH inhibitor). This is distinct from some GH secretagogues that additionally inhibit somatostatin release. The result is that Ipamorelin-stimulated GH pulses remain subject to normal somatostatin-mediated negative feedback, which some researchers consider a more physiological stimulation pattern.
---
Key Research Data
Body Composition and GH Response
Animal studies in rats and other models have examined Ipamorelin's effects on body composition under various conditions:
- •Lean mass: GH secretagogue studies in elderly and obese animal models have consistently shown that GHS-R1a agonists can preserve or increase lean mass under conditions of GH deficiency
- •Fat mass: IGF-1 elevation (downstream of GH) is associated with reduced adiposity in animal models; Ipamorelin studies in obese rats demonstrated modest reductions in fat mass over extended administration
- •Bone density: GH secretagogues including Ipamorelin have demonstrated effects on trabecular bone density in animal aging models, consistent with GH/IGF-1 axis effects on bone remodeling
GH Pulse Characteristics
Ipamorelin produces discrete GH pulses when administered as bolus injections. Research has characterized these pulses as similar in amplitude and duration to natural GH pulses, distinguishing Ipamorelin from continuous-acting GH secretagogues. This pulsatile pattern is thought to be more consistent with physiological GH secretion.
Post-Surgical Models
Some animal research has examined Ipamorelin specifically in post-operative contexts, including studies on GI motility recovery and nutrient absorption following abdominal surgery — applications that overlap with its ghrelin-mimetic properties beyond GH stimulation.
---
Subcutaneous Administration in Research
Ipamorelin research protocols in animal models have most commonly used subcutaneous (SC) injection, reflecting:
- •Peptide stability: Minimal degradation from SC tissue before systemic absorption
- •Bioavailability: SC administration achieves reliable systemic peptide levels in animal models
- •Practical research application: SC injection is well-established in preclinical rodent research methodology
The amidated C-terminus and D-amino acid residues in Ipamorelin's structure confer resistance to peptidase degradation, contributing to its moderate half-life (~2 hours in rodent models) compared to endogenous ghrelin (~30 min).
---
Platform Pricing
For current Ipamorelin research pricing across verified suppliers, compare live listings at peptides.so/compare/ipamorelin and the Ipamorelin peptide page.
Based on current platform data, Ipamorelin 5mg research vials are available from established suppliers. Use the Peptides Calculator to estimate quantities and costs for research protocols.
---
Synergy with CJC-1295: Different Receptor, Additive Release
The CJC-1295 + Ipamorelin combination is arguably the most commonly studied GH secretagogue combination in research literature. The rationale is mechanistically grounded:
Two Receptor Systems, One Outcome
- •CJC-1295 → GHRH receptor (Gαs/cAMP) → amplifies GH pulse amplitude and synthesis
- •Ipamorelin → GHS-R1a (Gαq/calcium) → triggers GH pulse timing and exocytosis
These receptor systems are pharmacologically distinct and activate GH release through separate intracellular pathways. When both are active simultaneously, they produce additive GH release — greater than either compound alone. This mirrors the natural synergy between endogenous GHRH (GHRH receptor) and ghrelin (GHS-R1a) that normally coordinates pituitary GH secretion.
The selectivity of Ipamorelin also makes it an attractive partner peptide: when combined with CJC-1295, the stack produces GH release without the cortisol/prolactin elevations that would occur with GHRP-2 or GHRP-6. This has made CJC-1295 + Ipamorelin the de facto reference combination in GH secretagogue research.
For detailed protocol considerations, see the CJC-1295 + Ipamorelin Stack Research Guide 2026.
Additional GH secretagogue context: Body Composition GH Peptide Stack Guide 2026.
---
Research Quality Standards
Research-grade Ipamorelin should meet:
- •Molecular weight: ~711.86 Da (confirm by mass spec)
- •Sequence: Aib-His-D-2Nal-D-Phe-Lys-NH₂
- •HPLC purity: ≥98%
- •Storage: Lyophilized at -20°C; reconstituted at 4°C, use within 30 days
Compare supplier listings and documentation at peptides.so/compare/ipamorelin.
---
Summary
Ipamorelin is the most selective growth hormone secretagogue peptide in common research use. Its defining characteristic — potent GH release without ACTH/cortisol or prolactin elevation — was established in the 1998 Novo Nordisk study (PMID 9849822) and has been consistently reproduced in subsequent research. It acts via GHS-R1a using a distinct mechanism from GHRH receptor agonists like CJC-1295, making the combination of the two compounds a mechanistically rational and frequently studied approach to GH secretagogue research. Ipamorelin's clean selectivity profile, moderate half-life, and well-characterized pharmacology make it one of the most useful reference compounds in GH secretagogue research.
---
> For Research Purposes Only. Ipamorelin is not approved by the FDA or any regulatory authority for human therapeutic use. This article is intended for educational purposes and for individuals with appropriate research credentials. Not for human use.
---
Ipamorelin's Structural Basis for Selectivity
The structural chemistry underlying Ipamorelin's selectivity is worth examining for researchers interested in GHS-R1a pharmacology. Key structural features:
Aib (alpha-aminoisobutyric acid) at position 1: This non-proteinogenic amino acid is alpha-methyl alanine. Its inclusion constrains the peptide backbone conformation and provides resistance to aminopeptidase cleavage — contributing to Ipamorelin's ~2-hour half-life (compared to ~30 minutes for endogenous ghrelin).
D-2-Naphthylalanine (D-2Nal) at position 3: The D-stereochemistry and bulky naphthyl group fit the hydrophobic binding pocket of GHS-R1a with high affinity for GH release, but apparently does not engage the accessory sites responsible for ACTH/cortisol-stimulating activity seen with earlier GHRPs.
D-Phenylalanine (D-Phe) at position 4: D-Phe contributes to GHS-R1a binding affinity while the D-stereochemistry prevents cleavage by endopeptidases at this position.
C-terminal amidation (Lys-NH₂): The amidated C-terminus improves metabolic stability and receptor binding. Peptides with a free C-terminal carboxyl are more susceptible to carboxypeptidase degradation.
This carefully optimized structure explains how Ipamorelin achieves excellent GHS-R1a engagement for GH release while avoiding the off-target receptor/binding site interactions that produce cortisol and prolactin responses with less selective GHRPs.
---
Comparative Pharmacology: GH Response Profiles
Research has characterized the specific GH response patterns that different GHS-R1a agonists produce:
Ipamorelin GH pulse characteristics:
- •Onset: GH elevation begins within 15–30 minutes of administration in rodent models
- •Peak: Maximum GH concentrations typically reached at 30–60 minutes
- •Duration: Pulse returns to baseline within 2–3 hours
- •Amplitude: Comparable to GHRP-6 in head-to-head rodent studies; modest compared to GHRP-2 at equivalent molar doses
Comparison with GHRP-6:
GHRP-6 is a hexapeptide that produces robust GH release but with significant ghrelin-like side effects: strong appetite stimulation, gastric motility effects, and mild cortisol elevation. In head-to-head studies, Ipamorelin matches GHRP-6 in GH release while producing none of the appetite/ghrelin-like effects.
Comparison with GHRP-2:
GHRP-2 is the most potent GHS-R1a agonist in common research use but produces substantial ACTH and cortisol elevation in addition to GH release. In head-to-head models, GHRP-2 produces approximately 3-5x greater cortisol response than Ipamorelin at GH-equivalent doses. This makes Ipamorelin preferable for research designs where isolated GH effects are the experimental target.
For a detailed comparison, see Ipamorelin vs GHRP-2: Growth Hormone Secretagogue Comparison for Researchers (2026) and Ipamorelin vs GHRP-6: Research Comparison Guide 2026.
---
GH Pulse vs. Continuous GH Elevation: Research Context
An important conceptual distinction in GH secretagogue research is the difference between pulsatile GH release (as produced by Ipamorelin) and continuous GH elevation (as produced by long-acting agents like pegylated GH or CJC-1295 DAC).
Why pulsatility matters:
Endogenous GH is secreted in discrete pulses — typically 6–12 pulses per 24 hours in adults, with the largest pulse occurring shortly after sleep onset. The pulsatile pattern is not simply a delivery mechanism — it appears to have distinct biological significance:
- •Liver GH receptor sensitivity: Continuous GH exposure causes GH receptor downregulation on hepatocytes, reducing IGF-1 production. Pulsatile GH preserves receptor sensitivity.
- •Differential gene regulation: Some GH-dependent genes show preferential activation by pulsatile vs. continuous GH patterns in animal studies.
- •Metabolic effects: Continuous vs. pulsatile GH exposure has been shown to have different effects on fat metabolism in animal models.
Ipamorelin, producing discrete GH pulses when administered as bolus doses, is considered to more closely mimic endogenous GH secretion patterns than long-acting GH secretagogues or direct GH administration. This is a key distinction in research designs examining physiological GH axis function.
---
Ipamorelin in Sleep Research
One underappreciated research application of Ipamorelin is its connection to sleep and GH secretion:
In healthy individuals, the largest GH pulse of the day occurs during the first slow-wave sleep (SWS) episode. This GH-sleep connection is mediated partly by hypothalamic GHRH and ghrelin signaling. Research in animal models has examined whether GHS-R1a agonists like Ipamorelin:
- •Alter sleep architecture (SWS duration, REM patterns)
- •Potentiate the nocturnal GH pulse
- •Affect circadian regulation of GH release
Published rodent studies on ipamorelin's sleep effects suggest potential SWS-promoting activity, connecting its GH secretagogue properties to sleep quality research — an area of growing interest in aging and longevity research.
For a research stack that specifically addresses sleep applications, see the Sleep & Recovery Peptide Stack 2026: Epithalon + DSIP + Ipamorelin + Selank.
---
Post-Surgical Gut Motility Research
A distinct and specifically interesting application of Ipamorelin in the research literature is post-operative gut motility. As a ghrelin-mimetic, Ipamorelin activates the ghrelin/motilin signaling pathway in the enteric nervous system, which is relevant to gastrointestinal motility research.
Post-operative ileus (POI) — the temporary loss of normal gut motility following abdominal surgery — is a clinically significant complication. Research has examined ghrelin analogs including Ipamorelin for potential prokinetic effects in POI models, given ghrelin's established role in stimulating gastric motility via vagal and direct enteric mechanisms.
This application positions Ipamorelin at the intersection of GH secretagogue research and GI motility research — quite distinct from its primary classification as a "GH peptide."
---
Long-Term Research Considerations
For researchers designing longer-duration Ipamorelin studies, several considerations arise from the literature:
Tachyphylaxis risk: Like all GHS-R1a agonists, Ipamorelin can produce some degree of receptor desensitization with continuous high-frequency exposure. Published rodent studies suggest this is less pronounced than with some first-generation GHRPs, and cycling protocols (administration windows with rest periods) may attenuate this effect.
GH axis negative feedback: Ipamorelin-stimulated GH elevation eventually increases IGF-1, which provides negative feedback to the hypothalamic-pituitary axis — reducing subsequent GH pulse amplitude. This is physiological and part of the normal GH axis regulation; it means that very high-dose or continuous Ipamorelin administration may see diminishing GH returns over time.
IGF-1 monitoring in research: In longer animal studies using Ipamorelin, tracking serum IGF-1 as a downstream GH axis marker is standard practice — providing more integrated information about GH axis activation than GH alone (GH has a short serum half-life and significant pulsatile variation, while IGF-1 is more stable and reflects integrated GH exposure).
---
Research Quality Assessment
When evaluating Ipamorelin research quality, key parameters include:
Certificate of Analysis verification:
- •Sequence confirmation by Edman degradation or mass spectrometry
- •Molecular weight: 711.86 Da (confirm MW within ±2 Da)
- •HPLC purity: ≥98%, with single dominant peak
- •Absence of D/L isomer contamination (epimerization of the D-amino acids would reduce GHS-R1a affinity)
Common quality issues in research market:
- •Incorrect stereochemistry (L-Phe instead of D-Phe) reduces selectivity profile
- •Truncated sequences missing Aib or Lys
- •Low purity preparations with ~5-15% related impurities
Detailed comparison of available suppliers is at peptides.so/compare/ipamorelin. For dosing and protocol design context, see Ipamorelin Dosage Protocol Guide 2026.
References
- •PMID: 42578445
- •PMID: 39043357
- •PMID: 30282322